Unibest
← Back to patent-cliff list

CAS 108-30-5

2,5-Dioxotetrahydrofuran

Codes: SALM-029, (IV)91299-1-a

Application context (from source-drug indications)

AsthmaBudesonide/Salmeterol xinafoatePlasmodium infectionArtesunate/Pyronaridine PhosphateCOVID-19Artesunate/Pyronaridine PhosphateFalciparum malariaArtesunate/Pyronaridine PhosphatePlasmodium infectionArtesunate/Mefloquine HydrochlorideFalciparum malariaArtesunate/Mefloquine HydrochloridePlasmodium infectionArtesunateIntestinal neoplasmArtesunateColon cancerArtesunateCervical intraepithelial neoplasiaArtesunateHIV infectionArtesunateCervical cancerArtesunateChronic obstructive pulmonary diseaseSalmeterol xinafoateAsthmaSalmeterol xinafoateExercise-induced asthmaSalmeterol xinafoateBronchospasmSalmeterol xinafoateSubmental fat accumulationSalmeterol xinafoate

Source drugs (routes using this intermediate)

DrugTierExpiry
Budesonide/Salmeterol xinafoateTier C — Watch / trade-
Artesunate/Pyronaridine PhosphateTier C — Watch / trade-
Artesunate/Mefloquine HydrochlorideTier C — Watch / trade-
ArtesunateTier C — Watch / trade-
Salmeterol xinafoateTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Budesonide/Salmeterol xinafoateOptimised routesteps: 11total yield: 1.3 g (Salmeterol xinafoate)
SALM-025→methyl 5-acetyl-2-hydroxybenzoate→SALM-026→SALM-027→N-benzyl-6-(4-phenylbutoxy)hexan-1-amine→SALM-028→SALM-029→SALM-030→SALM-031→SALM-032→4-phenylbutan-1-ol→SALM-033→SALM-034
Artesunate/Pyronaridine PhosphateOptimised routesteps: 3total yield: /
Dihydroartemisinic acid→(1R,4S,5R,8S,9R,12S,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one→(1R,4S,5R,8S,9R,12R,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol→2,5-Dioxotetrahydrofuran
Artesunate/Mefloquine HydrochlorideOptimised routesteps: 3total yield: /
Dihydroartemisinic acid→(1R,4S,5R,8S,9R,12S,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one→(1R,4S,5R,8S,9R,12R,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol→2,5-Dioxotetrahydrofuran
ArtesunateOptimised routesteps: 3total yield: /
Dihydroartemisinic acid→(1R,4S,5R,8S,9R,12S,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one→(1R,4S,5R,8S,9R,12R,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol→2,5-Dioxotetrahydrofuran
Salmeterol xinafoateOptimised routesteps: 11total yield: 1.3 g (Salmeterol xinafoate)
SALM-025→methyl 5-acetyl-2-hydroxybenzoate→SALM-026→SALM-027→N-benzyl-6-(4-phenylbutoxy)hexan-1-amine→SALM-028→SALM-029→SALM-030→SALM-031→SALM-032→4-phenylbutan-1-ol→SALM-033→SALM-034

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.